Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)287.05K
Market Cap
$40.58M
Enterprise Value$40.95M
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$59.08K
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding11,304,697
10 Day Avg. Volume291,236
30 Day Avg. Volume287,052
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.63K
Enterprise Value/Ebitda-2.47
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Platform Spinoff (withZeta.ai)Spinning out withZeta.ai is a structural move to create a standalone AI-enabled product business that could generate recurring licensing/subscription revenue, attract strategic investors, and isolate risk between software and drug-development efforts, improving long-term strategic optionality.
Clinical & Regulatory ProgressTangible clinical readouts, IND clearance and orphan designations materially de-risk specific assets versus preclinical programs. These milestones increase partnerability and regulatory optionality, improving the probability of out-licensing, collaborations, or later-stage financing tied to validated programs.
Low LeverageMinimal debt reduces insolvency and interest-service risk for a development-stage biotech, preserving flexibility to fund R&D through equity or partnerships. Low leverage supports operational runway management and lowers mandatory cash outflows while pursuing clinical milestones.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flow mean the company cannot self-fund its development pace. This structural cash consumption forces recurrent financing or partnerships, increasing dilution risk and constraining long-term planning absent material revenue or transformational deals.
No Revenue / Ongoing LossesAbsence of product or licensing revenue leaves value hinge on future clinical success and partnership monetization. Ongoing operating losses create structural dependence on capital markets and make long-term sustainability contingent on binary R&D outcomes rather than steady commercial cash flows.
Financing Dependence & Dilution RiskRecent modest capital raise and warrant structures underscore reliance on external funding. Small proceeds versus burn, investor rights and potential warrant dilution create execution risk for the spinoff and pipeline funding, pressuring equity holders until sustainable revenue or large partnerships emerge.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $40.58M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 71 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 15, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 11,304,697 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.69%
12-Months-Change
Fundamentals
Return on Equity
-0.97%
Trailing 12-Months
Asset Growth
-65.76%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
20.30% Insiders
3.78% Mutual Funds
10.76% Other Institutional Investors
61.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---